The FDA approved the vaccine, Dengvaxia, subject to the condition that it can be used to treat people aged 9 to 16 with a laboratory-confirmed prior infection and living in areas where the disease is endemic (occurs regularly through the year).
In the US, the disease is particularly prevalent in Puerto Rico and a few other offshore territories and protectorates.
Dengvaxia was first approved in Mexico in 2015 and remains the world’s only approved vaccine against dengue but was subject to massive controversy when researchers found that it could worsen dengue in some people.
The Philippines is the only country in the world that has broadly used Dengvaxia, however, it revoked Sanofi’s product license and suspended the use of the vaccine after the company announced the findings of its post-marketing research.
A probe in Philippines also found ‘Causal Association’ between deaths and Sanofi Dengue Vaccine. Sanofi had however denied that its vaccine, the world’s first against dengue, had caused any deaths.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.